Bicara Therapeutics (BCAX) President & COO exercises 18,750 options and sells 18,750 shares
Rhea-AI Filing Summary
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp reported an option exercise and same‑day share sale in Bicara Therapeutics Inc. On 2026-08-10 he exercised 18,750 stock options at an exercise price of $3.7898 per share, receiving 18,750 shares of common stock. The same day, he sold 18,750 common shares at a weighted average price of $27.9751 per share, with individual sale prices ranging from $27.56 to $28.41, pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Following the derivative transaction, 51,752 stock options remained reported outstanding, expiring on 2033-04-05, from a grant that vests in sixteen equal quarterly installments after April 5, 2023, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 18,750 shares ($453K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Cohlhepp Ryan
Role
President and COO
Sold
18,750 shs ($525K)
Approx. gross sale proceeds
$525K
Approx. exercise cost
$71K
Approx. pre-tax spread
$453K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 18,750 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 18,750 | $3.7898 | $71K |
| Sale | Common Stock F1, F2 | 18,750 | $27.9751 | $525K |
Holdings After Transaction:
Stock Option (Right to Buy) — 51,752 shares (Direct);
Common Stock — 181,641 shares (Direct)
Footnotes (3)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.56 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options exercised: 18,750 shares
Exercise price: $3.7898 per share
Shares sold: 18,750 shares
+4 more
7 metrics
Options exercised
18,750 shares
Stock options exercised into common stock on 2026-08-10
Exercise price
$3.7898 per share
Exercise price of stock options converted to common stock
Shares sold
18,750 shares
Common stock sold on 2026-08-10
Weighted average sale price
$27.9751 per share
Weighted average price for shares sold, with trades from $27.56 to $28.41
Remaining options
51,752 options
Stock options reported following the derivative transaction
Option expiration
2033-04-05
Expiration date of the option grant involved in the exercise
10b5-1 plan adoption date
March 31, 2026
Date the Rule 10b5-1 trading plan governing these trades was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vesting financial
"shares underlying this option vest in sixteen equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Bicara Therapeutics (BCAX) President and COO Ryan Cohlhepp report on this Form 4?
Ryan Cohlhepp exercised 18,750 stock options at $3.7898 per share and sold 18,750 common shares at a weighted average price of $27.9751 on 2026-08-10, all as reported in this Form 4.
How many Bicara Therapeutics (BCAX) options did Ryan Cohlhepp exercise and at what price?
He exercised 18,750 stock options for Bicara Therapeutics common stock at an exercise price of $3.7898 per share on 2026-08-10, converting them into an equal number of common shares.
Was the Bicara Therapeutics (BCAX) insider transaction under a Rule 10b5-1 plan?
Yes. The transactions were executed pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2026, according to the referenced footnote.
How many Bicara Therapeutics (BCAX) options does Ryan Cohlhepp report remaining after this transaction?
Following the reported option exercise, he reports 51,752 stock options outstanding, with an expiration date of 2033-04-05, linked to a grant vesting in sixteen equal quarterly installments.
What are the vesting terms of the Bicara Therapeutics (BCAX) options involved in this Form 4?
The options underlying this transaction vest in sixteen equal quarterly installments after April 5, 2023, and vesting is subject to Ryan Cohlhepp’s continued service on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
